BUZZ-Incyte falls on weak annual forecast for skin disorder drug

Drugmaker Incyte Corp's shares INCY.O fall 7.2% to $68.8

Co expects 2025 sales of skin-disorder drug Opzelura to be between $630 million and $670 million, below analysts' estimates of $671 million - data compiled by LSEG

Brokerage BMO Capital Markets says the downbeat forecast potentially suggests a slowing of revenue expansion in vitiligo

Vitiligo is a chronic autoimmune disorder that causes white patches to appear on the skin

Q4 sales of Opzelura came in at $161.6 million, beating estimates of $149.9 million

Q4 sales of blood-cancer drug Jakafi rose 11% to $773.1 million vs estimates of $744.9 million

Co sees annual sales for Jakafi of $2.93 bln to $2.98 bln, above estimates of $2.93 bln

Stock rose 5.5% in 2024